Articles On MGC Pharmaceuticals (ASX:MXC)

Title Source Codes Date
MGC Pharmaceuticals 'in a race to get as much applications for CimetrA so we can open in 2022'

Proactive Investors MXC 7 hours ago
MGC Pharmaceuticals raises fresh capital to fund next steps in COVID treatment program

Proactive Investors MXC 1 week ago
MGC Pharmaceuticals raises £5.5mln to fund emergency use authorisation for Covid treatment

It said it plans to begin the approval process for CimetrA in India before rolling it out to a total of five countries in central and eastern Europe and central Asia

Proactive Investors MXC 1 week ago
Closing Bell: Lithium debut goes up, health stock debut gets smashed

The ASX returned to positive territory today as investors began to shrug off fears of the omicron variant, but the bourse is still well below levels seen last week. While utilities lost over 1%, most other sectors gained with telcos being t...

Stockhead MXC 1 week ago
MGC Pharmaceuticals (ASX:MXC) halts trade following ArtemiC order

MGC Pharmaceuticals (MXC) places its shares in a trading halt while it plans the details of an upcoming capital raising The company will remain in the halt until December 2 or when more details are released, whichever occurs first On Nov...

themarketherald.com.au MXC 1 week ago
MGC Pharmaceuticals (ASX:MXC) completes $1m ArtemiC order

MGC Pharmaceuticals (MXC) completes production of the €650,000 (A$1.01 million) ArtemiC order from Swiss PharmaCan (SPC) MGC Pharma expects to receive the full amount by early December, delivering its best quarter and half-yearly revenue r...

themarketherald.com.au MXC 1 week ago
MGC Pharmaceuticals completes production of ArtemiC A$1 million order for global distributor Swiss PharmaCan

“With the continuing outbreaks of COVID-19, not only in Europe but globally, we expect to see continued growth in the demand for COVID-19 treatments for those people who contract the disease,” says MD.

Proactive Investors MXC 1 week ago
MGC Pharma US partnership validated after receiving first payment for US$24m order of CimetrA

The US$750k received today is just the first part of the US$24m three-year agreement with US distributor, AMC Holdings. European-based biotech MGC Pharma (ASX:MXC) has received the full US$750k cash deposit from its US distributor AMC Holdi...

Stockhead MXC 2 weeks ago
MGC Pharmaceuticals receives full cash deposit from AMC for CimertrA order

The bio-pharma group also announced that AMC has engaged Morgan Lewis & Bockius, a leading US pharmaceutical sector law firm, to seek FDA approval for its CimetrA product

Proactive Investors MXC 2 weeks ago
Cannabis stocks with high returns- CAU, LGP, LV1, MXC

Highlights Cannabis-based medicine and products businesses have expanded significantly in the past couple of years. The market is expected to grow at a CAGR of over 32.5% between 2021 to 2028. CAU, LGP, LV1, MXC are a few stocks with...

Kalkine Media MXC 1 month ago
MGC Pharmaceuticals (ASX:MXC) completes construction of Maltese production facility

MGC Pharmaceuticals (MXC) completes the construction phase of the CimetrA production facility in Malta on schedule The company says the facility will have the capacity to produce over 20,000 units of CimetrA in liquid dose form per day – d...

themarketherald.com.au MXC 1 month ago
MGC Pharma opens new production facility in Malta, now set to ramp up sales of CimetrA

The new facility in Malta sets MGC Pharma up to meet the rapidly increasing demand for its COVID-19 drug, CimetrA. Europe-based biotech MGC Pharma (ASX:MXC) is set to ramp up its manufacturing and global distribution, after completing its n...

Stockhead MXC 1 month ago
MGC Pharmaceuticals' Malta facility completed on time and to budget

The company is now moving onto the equipment fit-out and commissioning phase

Proactive Investors MXC 1 month ago
MGC Pharmaceuticals (ASX:MXC) granted Israeli study approval

MGC Pharmaceuticals (MXC) sees the Israeli Ministry of Health grant approval for a global dosing study for treating the effects of COVID-19 using CimetrA The company will recruit 240 patients into the study, with dosing sites in Israel, S...

themarketherald.com.au MXC 1 month ago
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

Stockhead MXC 1 month ago
MGC Pharmaceuticals (ASX:MXC) share price climbs on study approval

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is shooting higher and is currently up around 2% at 4.9 cents. Earlier in the day it was up to 5.1 cents, a gain of around 6% on the previous closing price. MGC shares have been in the gre...

Motley Fool MXC 1 month ago
MGC Pharmaceuticals gets the regulatory green light to start dosing Covid patients

The Israeli authorities will oversee the study, which will involve 240 people in three countries

Proactive Investors MXC 1 month ago
MGC Pharmaceuticals' latest record sales good vector of progress' for much stronger quarter ahead

Proactive Investors MXC 1 month ago
With record growth in 2021, MGC Pharma’s Q1 trading update confirmed it’s laid the foundation for a global expansion

MGC Pharma’s Q1 results saw the company continue to build strong foundations for future growth. Europe-based biotech MGC Pharma (ASX:MXC) has delivered another strong quarter of cash receipts and phytocannabinoid sales, as it strengthens i...

Stockhead MXC 1 month ago
MGC Pharmaceuticals posts record sales after strong quarter

The latest quarter delivered nearly US$1mln of cash receipts and US$564,000 of Phytocannabinoid medicine sales

Proactive Investors MXC 1 month ago
MGC Pharmaceuticals advances phase 3 clinical trial of CimetrA for the treatment of COVID-19

Early prevention of cytokine storm appears to be an effective method of treatment in mild and moderate COVID-19 cases.

Proactive Investors MXC 1 month ago
MGC Pharma lands milestone US$3 million CimetrA purchase order

MGC Pharma has secured its biggest order for any product with its US distributor AMC Holdings confident CimetrA may be the much-needed wonder drug to treat COVID-19. Europe-based biotech MGC Pharma (ASX:MXC) has secured its largest ever or...

Stockhead MXC 2 months ago
MGC Pharmaceuticals 'excited to move forward on collaborative process' with partner AMC Holdings

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals moves forward on collaborative process with partner AMC Holdings

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals says AMC Holdings places first order under US$24mln supply deal

The US$3mln purchase order is for CimetrA, MGC’s curcumin and Boswellia compound, which has shown early promise in treating the symptoms of COVID-19

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals Share Price Up on Order Announcement (ASX:MXC)

The units were ordered to fast track the approval process for the medication to be distributed and sold in the US. The expedited order buoyed the market. MGC Pharmaceuticals [ASX:MXC] share price is currently up 6.90%. The post MGC Pharmac...

MoneyMorning MXC 2 months ago
MGC Pharma receives first order in the US, as it seeks to fast track commercialisation of CimetrA

The initial order in the US is expected to fast track the regulatory approval for CimetrA, and establish clinical trials for MGC Pharma’s other drugs, CogniCann and CannEpil. Europe-based biotech MGC Pharma (ASX:MXC) has made crucial progre...

Stockhead MXC 2 months ago
Why the MGC Pharmaceuticals (ASX:MXC) share price is leaping 5%

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is clicking higher on Thursday and is currently trading at 6.1 cents. MGC shares are lifting after the company announced updates to its new production and supply agreement out of the Unit...

Motley Fool MXC 2 months ago
Australia… One Hour In… ASX200 up 61

ShareCafeAustralia… One Hour In… ASX200 up 61 ASX200 up 61 points (0.8%) to 7258.   Commonwealth Bank (+1%); don’t forget the buy back closes tomorrow. Fortescue (+0.7%); operations at Solomon Hub have been suspended due to a significant i...

ShareCafe MXC 2 months ago
MGC Pharmaceuticals' US commercial partnership gaining early traction

The order of 1,000 units of CimetrA is part of a landmark deal with AMC worth a minimum of US$24mln

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals hails US partnership as AMC orders possible COVID-19 treatment

The order of 1,000 units of CimetrA is part of a landmark deal with AMC worth a minimum of US$24mln

Proactive Investors MXC 2 months ago
Here’s why this fundie expects MGC Pharma’s stock price to more than double

The research note out of fundie Canaccord says that MGC Pharma has several tailwinds, including near term revenues and clinical trials potential over the next year. UK-based wealth manager Canaccord Genuity has just initiated a speculative...

Stockhead MXC 2 months ago
MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Investors MXC 2 months ago
MGC Pharma makes inroads in the fight against COVID-19, getting a regulatory nod in Germany and a successful trial in India

In major milestones, MGC Pharma’s non-cannabis products ArtemiC and CimetrA got further boosts today in both Germany and India which will see the products being sold in more territories. Europe-based biotech MGC Pharma (ASX:MXC) has made fu...

Stockhead MXC 2 months ago
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc

The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the broader ASX 200 index which rose by 0.73%. Mergers and acquisitions were very much the order of the day in the Health sector today. The countr...

Stockhead MXC 2 months ago
MGC Pharmaceuticals' gets access to EU market for ArtemiC to escalate EU exposure and sales

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals says ArtemiC gets green light for EU sales; Indian trial shows efficacy in severe COVID-19 patients

Wednesday's statement brought two significant developments for the ArtemiC product group

Proactive Investors MXC 2 months ago
MGC Pharmaceuticals Shares Lift on Landmark UK Import Permit (ASX:MXC)

MGC Pharmaceuticals said this marks the first time an epilepsy treatment containing THC and still undergoing clinical trials was approved by UK authorities for import.   The news saw MGC Pharmaceuticals [ASX:MXC] shares jump 10% at the time...

MoneyMorning MXC 2 months ago
MGC Pharma share price soars after CannEpil scores UK-first import deal

Europe-based biotech MGC Pharma has achieved a major milestone in its treatment of refractory epilepsy with CannEpil+ approved for import in the UK.  MGC Pharma (ASX:MXC) has been granted a landmark UK import permit for its drug CannEpil+...

Stockhead MXC 2 months ago
Sluggish ASX can’t keep pace with Wall Street’s gains

MGC Pharmaceuticals Ltd is up 11.67% having achieved a new landmark for the UK cannabis market as CannEpil+, a cannabis-based treatment for epilepsy, has been approved for import by the UK authorities.

Proactive Investors MXC 2 months ago
ASX Health Stocks: Cannabis play Cronos scoots 19% higher on merger news, Telix gets FDA nod for clinical trial

The ASX 200 health stocks index (XHJ) fell by 0.90% at the time of writing, compared to the broader ASX 200 index which fell by 0.40%. Medicinal cannabis play, Cronos Australia (ASX:CAU), has jumped by 19% in morning trading, after announci...

Stockhead MXC 2 months ago
MGC Pharma (ASX:MXC) share price jumps 11% on UK approval

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is charging higher on Tuesday. In early trade, the cannabis company’s shares are up 11.5% to 6.7 cents. Why is the MGC Pharma share price charging higher? Investors have been bidding the M...

Motley Fool MXC 2 months ago
Market Highlights and 5 ASX Small Caps to watch on Tuesday

Wall Street snaps four-day losing streak In US stock markets, the S&P 500 rose by 0.23% and the Dow Jones climbed 0.76% – snapping their four-day losing streak. The tech-heavy Nasdaq however, inched lower by 0.07%. Energy stocks were th...

Stockhead MXC 2 months ago
MGC Pharmaceuticals boosted by UK import approval

CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months, as part of a trial.

Proactive Investors MXC 2 months ago
Weed Week: Cannabis-infused drinks market could reach US$2.8 billion by 2025

The Boston Beer Company (NYSE:SAM) is set to launch a new range of non-alcoholic cannabis-infused drinks in Canada with the help of Australian listed Althea Group Holdings’ (ASX:AGH) subsidiary. Peak processing Solutions will research and d...

Stockhead MXC 3 months ago
ASX Health Stocks: Neuroscientific pockets $25m R&D incentive, MGC Pharma jumps 15% on India approval for COVID-19 drug

Neurological disorder specialist, Neuroscientific Biopharma (ASX:NSB), announced that research work on its lead drug EmtinB has received a tax incentive rebate under the R&D Tax Incentive program. The company said that it has been grant...

Stockhead MXC 3 months ago
MGC Pharma’s lead product CimetrA one step closer to a registered medicine for COVID-19 patients in India

MGC Pharma has been given the green light to import its lead product CimetrA into India in a crucial step to being granted Emergency Use Authorisation to be registered as a medicine for treatment of COVID-19 patients. European-based biopha...

Stockhead MXC 3 months ago
MGC Pharmaceuticals reports strong phytocannabanoid sales

Revenues in the year to end June 2021 rose 43% with phytocannabanoid sales up 69%

Proactive Investors MXC 3 months ago
MGC Pharmaceuticals delivers year of growth for 2021 with phytocannabanoid sales totalling A$2 million

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Proactive Investors MXC 3 months ago
MGC Pharmaceuticals delivers year of growth for 2021 with phytocannabinoid sales totalling A$2 million

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Proactive Investors MXC 3 months ago